GIM-1213s
Several Targets
DiscoveryActive
Key Facts
About Georgiamune
Georgiamune is a private, preclinical-stage biotech leveraging a proprietary target discovery platform to develop novel immunomodulators. The company's strategy centers on rebalancing the immune system with first-in-class assets, including a dual-functioning antibody for cancer and small molecules that either inhibit or activate regulatory T cells (Tregs) for cancer and autoimmune diseases, respectively. Headquartered in Gaithersburg, MD, Georgiamune is building a portfolio aimed at large indications with high unmet need. It operates as a pre-revenue company with a team experienced in biopharma R&D.
View full company profile